



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

| |
|----------------------------|
| To NZX Limited; and |
| Name of listed issuer: |
| Date this disclosure made: |
| Date of last disclosure: |

| |
|----------------------------|
| Orion Health Group Limited |
| 3-Apr-18 |
| 10-Jul-17 |

Director or senior manager giving disclosure

| |
|---|
| Full name(s): |
| Name of listed issuer: |
| Name of related body corporate (if applicable): |
| Position held in listed issuer: |

| |
|--|
| Wayne Oxenham |
| Orion Health Group Limited (OHE) |
| Not applicable |
| Executive Vice President, Strategic Projects |

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

| |
|--|
| Class of affected quoted financial products: |
| Nature of the affected relevant interest(s): |
| For that relevant interest- |
| Number held in class before acquisition or disposal: |
| Number held in class after acquisition or disposal: |
| Current registered holder(s): |
| Registered holder(s) once transfers are registered: |

| |
|--|
| Ordinary shares in OHE (Shares) |
| Legal interest in Shares (acquisition of 77,066 Shares that vested to Wayne Oxenham under the Orion Health Restricted Stock Unit Scheme) |
| 20,403 Shares |
| 97,469 Shares |
| Wayne Oxenham |
| Wayne Oxenham |

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

| |
|---|
| Type of affected derivative: |
| Class of underlying financial products: |

| |
|----------------|
| Not applicable |
| Not applicable |

Details of affected derivative-

| |
|---|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
| A statement as to whether the derivative is cash settled or physically settled: |
| Maturity date of the derivative (if any): |
| Expiry date of the derivative (if any): |
| The price specified in the terms of the derivative (if any): |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |

| |
|----------------|
| Not applicable |

For that derivative, -

| |
|--|
| Parties to the derivative: |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |

| |
|----------------|
| Not applicable |
| Not applicable |

Details of transactions giving rise to acquisition or disposal

| |
|---|
| Total number of transactions to which notice relates: |
|---|

| |
|-----|
| One |
|-----|

Details of transactions requiring disclosure-

| |
|--|
| Date of transaction: |
| Nature of transaction: |
| Name of any other party or parties to the transaction (if known): |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration: |
| Number of financial products to which the transaction related: |

| |
|---|
| 3-Apr-18 |
| Wayne Oxenham was issued 77,066 Shares on conversion of the restricted stock units that vested under the Orion Health Restricted Stock Unit Scheme. |
| Not applicable |
| Not applicable |
| 2 |

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

| |
|---|
| Whether relevant interests were acquired or disposed of during a closed period: |
|---|

| |
|----|
| No |
|----|

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
 Date of the prior written clearance (if any):

Not applicable
 Not applicable


Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:
 Nature of relevant interest:
For that relevant interest,-
 Number held in class:
 Current registered holder(s):
For a derivative relevant interest,-
 Type of derivative:
Details of derivative,-
 The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
 A statement as to whether the derivative is cash settled or physically settled:
 Maturity date of the derivative (if any):
 Expiry date of the derivative (if any):
 The price's specified terms (if any):
 Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
 Parties to the derivative:
 If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Shares
 (a) Beneficial interest in Shares (b) Beneficial interest in Shares
 (a) 574,444 (b) 73,334
 (a) Wayne Oxenham, Lynne Oxenham and Oxenham Trusts Limited as trustees of the Mambo Business Trust (b) Orion Health Corporate Trustee Limited as trustee for the Orion Health Long Term Incentive Scheme
 Not applicable
 Not applicable

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
 Signature of director or officer:
 Date of signature:
 or
 Signature of person authorised to sign on behalf of director or officer:
 Date of signature:
 Name and title of authorised person:


 3-Apr-18
 Helen Dymond, Legal Counsel

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—
 (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
 (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.